Please login to the form below

Not currently logged in
Email:
Password:

Sandoz UK promotes Tim de Gavre to country head

He succeeds Stephan Eder who becomes country head for Sandoz Germany

Tim de GavreNovartis’ generics and biosimilar division Sandoz has appointed Tim de Gavre as its new country head for the UK.

De Gavre has served at Sandoz for seven years to date, initially joining as its global head of strategy for the biosimilars business unit based in Germany.

Prior that that he worked at McKinsey & Company and brings almost 20 years of healthcare, consulting and marketing experience to the firm.

He said: “I am immensely proud to be asked to lead the Sandoz UK team.

“As a market, the UK has one of the highest levels of generic use of any global market, and the NHS is also under severe cost pressures.

“Our combined portfolio of small molecule generics and biosimilars makes a significant different to medicines costs, and helps the NHS manage these cost-pressures.”

“As a company, Sandoz has an exciting portfolio of medicines and future product pipeline. I look forward to working with the Sandoz team, and in partnership with the NHS to help patients access these important medicines.”

De Gavre succeeds Stephan Eder, who will take over the role of country head for Sandoz Germany.

In that role Eder will be responsible for all commercial and medical activities for Sandoz, Hexal and 1A pharma in Germany.

2nd May 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics